ICV delivery approach for CNS gene therapy set for American Society of Gene and Cell Therapy meeting, Neurogene Inc.

ICV delivery approach for CNS gene therapy set for American Society of Gene and Cell Therapy meeting, Neurogene Inc.
Neurogene Inc. plans ICV gene therapy talk

Neurogene Inc. has announced plans to present new research on the rationale for intracerebroventricular (ICV) delivery in central nervous system (CNS)-targeted gene therapy at the upcoming American Society of Gene and Cell Therapy Annual Meeting.

The presentation aims to shed light on the potential effectiveness of ICV delivery methods in advancing gene therapies for neurological conditions. The company continues to advance its research in developing novel approaches for the treatment of CNS disorders through innovative delivery techniques.

Neurogene has recently expanded its executive team, naming Christy Shafer as Chief Commercial Officer. The company also added Christine Mikail to its board of directors, according to a prior announcement. These leadership changes support ongoing initiatives in CNS disorder research and development.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.